On September 6, 2022 Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its highly productive bacterial Mimicry drug discovery platform, reported that it will present two posters on its OncoMimics pipeline at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2022, which will be held September 9-13 in Paris, France (Press release, Enterome, SEP 6, 2022, View Source [SID1234619016]). The posters will focus on two clinical trials evaluating EO2401 to treat patients with recurrent glioblastoma (ROSALIE) and adrenocortical carcinoma (ACC) and malignant pheochromocytoma/paraganglioma (MPP) (SPENCER).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on Enterome’s poster presentations

ROSALIE study

Title: EO2401 (EO) therapeutic vaccine for patient (pts) with recurrent glioblastoma (GB):

phase 1/2 ROSALIE study

Authors: D. Reardon et al

Abstract number: 1223

Category: CNS tumours

Date: Saturday September 10th , 2022

Key highlights :

EO2401 is safe and well tolerated and generated immune responses in most evaluable patients.
ROSALIE (EOGBM1-18) proof-of-concept data has already shown strong immune responses in combination with an immune checkpoint inhibitor (nivolumab, Opdivo) and an anti-VEGF therapy (bevacizumab, Avastin), for the treatment of patients with first progression/recurrence of glioblastoma.
The addition of standard bevacizumab to the combination of EO2401 plus nivolumab led to an improvement in objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS)
The results of the second part of the study will be presented at ESMO (Free ESMO Whitepaper) Congress.

SPENCER study

Title: EO2401 (EO) therapeutic vaccine for patient (pts) with adrenocortical carcinoma (ACC) and malignant pheochromocytoma/paraganglioma (MPP): phase 1/2 SPENCER study

Authors: E. Baudin et al

Abstract number: 3149

Category: Adrenal cancer

Presenter: Dr. Eric Baudin, Associate Professor and Head of the Endocrine Oncology Unit at Gustave Roussy (Villejuif, France)

Date/Time: Oral Presentation- Monday September 12th, 2022 at 9.40 am CEST

Key highlights:

EO2401 in combination with nivolumab has demonstrated strong immune responses and clinical efficacy in patients with ACC, which was defined retrospectively using a set of clinical parameters.
A randomized Phase 2 trial with an expanded subpopulation of patients with ACC is planned to start in the coming months.
An update on the ongoing expanded study for treatment of patients with MPP will be presented at ESMO (Free ESMO Whitepaper) Congress.

On September 6, 2022 CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, reported that management will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022 (Press release, CymaBay Therapeutics, SEP 6, 2022, https://ir.cymabay.com/news/detail/541/cymabay-therapeutics-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference [SID1234619015]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 24th Annual Global Investment Conference

On September 6, 2022 Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, reported that the Company will participate in the following upcoming investor conferences taking place in New York (Press release, Arbutus Biopharma, SEP 6, 2022, View Source [SID1234619014]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 24th Annual Global Investment Conference (September 12-14, 2022)

Company Presentation: Tuesday, September 13th at 12:30 pm ET
Presenter: William Collier, President & Chief Executive Officer
Baird’s 2022 Global Healthcare Conference (September 13-14, 2022)

Fireside Chat: Wednesday, September 14th at 10:15 am ET
Presenters: William Collier, President & Chief Executive Officer; Dr. Gaston Picchio, Chief Development Officer; Michael McElhaugh, Chief Business Officer; and David Hastings, Chief Financial Officer
Live webcasts of the presentation and fireside chat can be accessed through the Investors section of Arbutus’ website at www.arbutusbio.com. An archived replay of the webcast will be available on the Arbutus website after the event.

On September 6, 2022 Almac Sciences, a member of the Almac Group, and University College Dublin (UCD), reported that they have been awarded a Science Foundation Ireland (SFI) ‘Frontiers for the Future’ grant (Press release, Almac, SEP 6, 2022, View Source [SID1234619013]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The €420,000 grant will enable the exploitation, for the first-time, of emerging enzymes such as ene-reductase (ERED) and carboxylic acid reductase (CAR) enzymes in continuous flow reactors to develop new routes to chemical products. Almac Sciences and UCD will work together to establish the use of enzymatic multi-step reactions in continuous flow reactors as readily and widely applicable tools for the sustainable synthesis of fine chemicals.

The project team, co-funded by Almac Sciences, will include one postdoctoral researcher and two PhD studentships over the next 4 years based primarily in UCD. Both PhD students, Ruairi Bannon and Philip Jamieson, have undertaken industry placements within Almac as part of their undergraduate studies. The placement has equipped them with key transferable skills and valuable insights into critical decision-making for flow processes with industrial relevance.

Lead academic at UCD, Dr Marcus Baumann said "This project will further build on our existing collaboration with Almac Sciences, strengthening expertise for continuous flow within Ireland with a focus on enhancing the application of continuous flow within the biocatalysis sphere."

Almac and UCD have collaborated on various projects over the last few years and have recently been awarded SSPC’s Industry Impact of the Year, recognising their joint development of continuous flow processes using enzymes.

Almac continues to enhance its flow service offering with a completed £500,000 investment to date already in place. This project further establishes Almac Sciences in the field of flow chemistry and builds on novel methodologies applicable for industrial scale transformations.

Dr Megan Smyth, Team Leader Custom and Flow Chemistry, Almac Sciences commented: "Collaborations such as these established with Marcus and UCD are of the utmost importance to us in Almac Sciences. By supporting development of students, we can ensure a pipeline of expertly trained flow chemists in line with our growing capabilities. For Ruairi and Philip, the opportunity to avail of expertise at Almac Sciences and UCD fosters key interdisciplinary skills and research excellence in the area of flow. I am excited to work closely with them both throughout their studies and wish them every success."

On September 6, 2022 AIM ImmunoTech Inc. (NYSE: American AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, reported Chris McAleer, Ph.D., Deputy Chief Science Officer of AIM, and William Mitchell, M.D. Ph.D., Chairman of the Board of Directors of AIM, will present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 8-10, 2022 (Press release, AIM ImmunoTech, SEP 6, 2022, View Source [SID1234619012]). In addition to management’s presentations, the Company is proud to announce its sponsorship of the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Title: Rintatolimod (Ampligen): An Investigational Immunomodulatory Agent Targeted at Cancers of High Unmet Need
Author: Christopher McAleer, Ph.D.
Date: Saturday, September 10

Title: The Mechanism of PAMP Restricted Rintatolimod in Limiting Systemic Inflammatory Responses
Author: William M. Mitchell, M.D., Ph.D.
Date: Saturday, September 10

Presentations will take place at the Cancer Genetics & Pharmacology Building at the Roswell Park Comprehensive Center.

For more information about the conference, visit: View Source

The presentations will be available on the AIM website once presented at the conference.